Shi Shennan, Lu Yalan, Long Qiwen, Wu Yanqing, Guo Yan, Chen Nipi, Wan Haitong, Jin Bo
School of Life Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 310007, China.
ACS Omega. 2025 Feb 25;10(9):9604-9612. doi: 10.1021/acsomega.4c10868. eCollection 2025 Mar 11.
Danhong injection (DHI), a Chinese patent compound injection, is widely used in the treatment of cardiovascular diseases (CVD) in China. However, the underlying mechanisms have not been fully elucidated. This study investigated the therapeutic effect and the underlying mechanisms of DHI against ischemia-reperfusion (I/R) injury and endothelial dysfunction (ED). Network pharmacology analysis revealed that DHI had six core active compounds (Danshensu, salvianolic acid A, salvianolic acid B, rosmarinic acid, protocatechualdehyde, and caffeic acid) and 19 potential targets in treating I/R injury. Notably, the regulation of apoptosis was significantly enriched, as indicated by the results of the gene ontology (GO) enrichment analysis. Molecular docking studies confirmed that these targets had high affinity with the active compounds of DHI. Finally, experimental validation in vivo and in vitro demonstrated that DHI could mitigate I/R injury and ED, potentially by reducing oxidative damage through the inhibition of apoptosis via the PTEN/AKT pathway. These findings significantly advance our understanding of the molecular mechanisms in DHI treatment and contribute further to promoting the clinical application of CVD.
丹红注射液（DHI）是一种中药复方注射剂，在中国广泛用于治疗心血管疾病（CVD）。然而，其潜在机制尚未完全阐明。本研究探讨了丹红注射液对缺血再灌注（I/R）损伤和内皮功能障碍（ED）的治疗作用及其潜在机制。网络药理学分析显示，丹红注射液具有六种核心活性成分（丹参素、丹酚酸A、丹酚酸B、迷迭香酸、原儿茶醛和咖啡酸）以及19个治疗I/R损伤的潜在靶点。值得注意的是，基因本体（GO）富集分析结果表明，凋亡调控显著富集。分子对接研究证实，这些靶点与丹红注射液的活性成分具有高亲和力。最后，体内和体外实验验证表明，丹红注射液可能通过PTEN/AKT途径抑制凋亡，减少氧化损伤，从而减轻I/R损伤和ED。这些发现显著推进了我们对丹红注射液治疗分子机制的理解，并进一步有助于促进心血管疾病的临床应用。
